<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35313253</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8952</ISSN><JournalIssue CitedMedium="Internet"><Volume>137</Volume><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology</Title><ISOAbbreviation>Clin Neurophysiol</ISOAbbreviation></Journal><ArticleTitle>The landscape of neurophysiological outcome measures in ALS interventional trials: A systematic review.</ArticleTitle><Pagination><StartPage>132</StartPage><EndPage>141</EndPage><MedlinePgn>132-141</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clinph.2022.02.020</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1388-2457(22)00191-2</ELocationID><Abstract><AbstractText Label="OBJECTIVE">We collated all interventional clinical trials in amyotrophic lateral sclerosis (ALS), which utilised at least one neurophysiological technique as a primary or secondary outcome measure. By identifying the strengths and limitations of these studies, we aim to guide study design in future trials.</AbstractText><AbstractText Label="METHODS">We conducted and reported this systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Eight databases were searched from inception. In total, 703 studies were retrieved for screening and eligibility assessment.</AbstractText><AbstractText Label="RESULTS">Dating back to 1986, 32 eligible interventional clinical trials were identified, recruiting a median of 30 patients per completed trial. The most widely employed neurophysiological techniques were electromyography, motor unit number estimation (including motor unit number index), neurophysiological index and transcranial magnetic stimulation (including resting motor threshold and short-interval intracortical inhibition). Almost 40% of trials reported a positive outcome with respect to at least one neurophysiological measure. The interventions targeted either ion channels, immune mechanisms or neuronal metabolic pathways.</AbstractText><AbstractText Label="CONCLUSIONS">Neurophysiology offers many promising biomarkers that can be utilised as outcome measures in interventional clinical trials in ALS. When selecting the most appropriate technique, key considerations include methodological standardisation, target engagement and logistical burden.</AbstractText><AbstractText Label="SIGNIFICANCE">Future trial design in ALS would benefit from a standardised, updated and easily accessible repository of neurophysiological outcome measures.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>GKT School of Medical Education, Faculty of Life Sciences and Medicine, King's College London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>M R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bashford</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute, Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK. Electronic address: james.bashford@kcl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>COV-LT-0022</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC/PC/14101</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC/PC/13071</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>EP/V050419/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Clin Neurophysiol</MedlineTA><NlmUniqueID>100883319</NlmUniqueID><ISSNLinking>1388-2457</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004576" MajorTopicYN="N">Electromyography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009482" MajorTopicYN="N">Neurophysiology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050781" MajorTopicYN="N">Transcranial Magnetic Stimulation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Drug trial</Keyword><Keyword MajorTopicYN="N">Electromyography</Keyword><Keyword MajorTopicYN="N">Motor unit number estimation</Keyword><Keyword MajorTopicYN="N">Neurophysiology</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>21</Day><Hour>20</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35313253</ArticleId><ArticleId IdType="pmc">PMC10166714</ArticleId><ArticleId IdType="doi">10.1016/j.clinph.2022.02.020</ArticleId><ArticleId IdType="pii">S1388-2457(22)00191-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bansal H., Singh L., Agrawal A., Leon J., Sundell I.B., Koka P.S. Therapy with bone marrow-derived autologous adult stem cells in quadriparesis due to motor neuron disease. J Stem Cells. 2016;11(1):15.</Citation><ArticleIdList><ArticleId IdType="pubmed">28296861</ArticleId></ArticleIdList></Reference><Reference><Citation>Bashford J., Baker M.R. Excitability in amyotrophic lateral sclerosis: what goes up must come down. Clin Neurophysiol. 2020;131:2617&#x2013;2620.</Citation><ArticleIdList><ArticleId IdType="pubmed">32927217</ArticleId></ArticleIdList></Reference><Reference><Citation>Bashford J., Mills K., Shaw C. The evolving role of surface electromyography in amyotrophic lateral sclerosis: a systematic review. Clin Neurophysiol. 2020;131(4):942&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7083223</ArticleId><ArticleId IdType="pubmed">32044239</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E., Chio A., Couratier P., Esteban J., Hardiman O., Logroscino G., et al. The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph Lateral Scler. 2011;12(1):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3513399</ArticleId><ArticleId IdType="pubmed">20698807</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E., Mennini T., Bendotti C., Bigini P., Logroscino G., Chio A., et al. The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure. Curr Med Chem. 2007;14(30):3185&#x2013;3200.</Citation><ArticleIdList><ArticleId IdType="pubmed">18220753</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi A., Alberici A., Cotelli M.S., Dell'Era V., Cantoni V., Bonetta E., et al. Cortico-spinal tDCS in ALS: A randomized, double-blind, sham-controlled trial. Brain Stimul. 2019;12(5):1332&#x2013;1334.</Citation><ArticleIdList><ArticleId IdType="pubmed">31204206</ArticleId></ArticleIdList></Reference><Reference><Citation>Bromberg M.B., Fries T.J., Forshew D.A., Tandan R. Electrophysiologic endpoint measures in a multicenter ALS drug trial. J Neurol Sci. 2001;184(1):51&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">11231032</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Miller R.G., Swash M., Munsat T.L. World Federation of neurology research group on motor neuron D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cashman N., Tan L.Y., Krieger C., Madler B., Mackay A., Mackenzie I., et al. Pilot study of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells in amyotrophic lateral sclerosis (ALS) Muscle Nerve. 2008;37(5):620&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pubmed">18335482</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Canosa A., Gallo S., Cammarosano S., Moglia C., Fuda G., et al. ALS clinical trials: do enrolled patients accurately represent the ALS population? Neurol. 2011;77:1432&#x2013;1437.</Citation><ArticleIdList><ArticleId IdType="pubmed">21956723</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz M.E., Shefner J.M., Schoenfeld D.A., Zhang H., Andreasson K.I., Rothstein J.D., et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol. 2006;60(1):22&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">16802291</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M., Barkhaus P.E., Nandedkar S.D., Swash M. Motor unit number estimation (MUNE): where are we now? Clin Neurophysiol. 2018;129(8):1507&#x2013;1516.</Citation><ArticleIdList><ArticleId IdType="pubmed">29804042</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M., Chio A., Dengler R., Hecht M., Weber M., Swash M. Neurophysiological measures in amyotrophic lateral sclerosis: markers of progression in clinical trials. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6(1):17&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">16036422</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M., Pinto S., Costa J., Evangelista T., Ohana B., Pinto A. A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11(5):456&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">20565333</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M., Swash M. Lower motor neuron dysfunction in ALS. Clin Neurophysiol. 2016;127(7):2670&#x2013;2681.</Citation><ArticleIdList><ArticleId IdType="pubmed">27117334</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Rubia JE. Impact of the combined treatment of liposomed polyphenols with dutasteride on the ALS patients; 2020. &lt;https://clinicaltrials.gov/ct2/show/NCT04654689#wrapper&gt;.</Citation></Reference><Reference><Citation>de la Rubia J.E., Drehmer E., Platero J.L., Benlloch M., Caplliure-Llopis J., Villaron-Casales C., et al. Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(1&#x2013;2):115&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">30668199</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai J., Sharief M., Swash M. Riluzole has no acute effect on motor unit parameters in ALS. J Neurol Sci. 1998;160:S69&#x2013;S72.</Citation><ArticleIdList><ArticleId IdType="pubmed">9851653</ArticleId></ArticleIdList></Reference><Reference><Citation>Fathi D., Nafissi S., Attarian S., Neuwirth C., Fatehi F. An overview of motor unit number index reproducibility in amyotrophic lateral sclerosis. Iran J Neurol. 2019;18(3):119&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6858602</ArticleId><ArticleId IdType="pubmed">31749933</ArticleId></ArticleIdList></Reference><Reference><Citation>Geijo-Barrientos E., Pastore-Olmedo C., De Mingo P., Blanquer M., Gomez Espuch J., Iniesta F., et al. Intramuscular injection of bone marrow stem cells in amyotrophic lateral sclerosis patients: a randomized clinical trial. Front Neurosci. 2020;14:195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7105864</ArticleId><ArticleId IdType="pubmed">32265627</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J., Rowe D.B., Kiernan M.C., Vucic S., Mathers S., van Eijk R.P.A., et al. Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(7&#x2013;8):595&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">31284774</ArticleId></ArticleIdList></Reference><Reference><Citation>Gooch C.L., Doherty T.J., Chan K.M., Bromberg M.B., Lewis R.A., Stashuk D.W., et al. Motor unit number estimation: a technology and literature review. Muscle Nerve. 2014;50(6):884&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pubmed">25186553</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal N.A., Berry J.D., Windebank A., Staff N.P., Maragakis N.J., van den Berg L.H., et al. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle Nerve. 2020;62(2):156&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7496557</ArticleId><ArticleId IdType="pubmed">31899540</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifols T. Efficacy and safety of plasma exchange with Albutein&#xae; 5% in patients with amyotrophic lateral sclerosis; 2020. &lt;https://clinicaltrials.gov/ct2/show/study/NCT02872142#wrapper&gt;.</Citation></Reference><Reference><Citation>Hannaford A., Pavey N., van den Bos M., Geevasinga N., Menon P., Shefner J.M., et al. Diagnostic utility of gold coast criteria in amyotrophic lateral sclerosis. Ann Neurol. 2021;89(5):979&#x2013;986.</Citation><ArticleIdList><ArticleId IdType="pubmed">33565111</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J.P., Altman D.G., Gotzsche P.C., Juni P., Moher D., Oxman A.D., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal M.K. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019;39(2):733&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Burke D, Bostock H. Nerve excitability measures: biophysical basis and use in the investigation of peripheral nerve disease, vol. 1. Peripheral Neuropathy: Elsevier; 2005. p. 113&#x2013;29.</Citation></Reference><Reference><Citation>Kiernan M.C., Vucic S., Cheah B.C., Turner M.R., Eisen A., Hardiman O., et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovalchuk M.O., Heuberger J., Sleutjes B., Ziagkos D., van den Berg L.H., Ferguson T.A., et al. Acute effects of riluzole and retigabine on axonal excitability in patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled. Crossover Trial Clin Pharmacol Ther. 2018;104(6):1136&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pubmed">29672831</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuwabara S. Open-label clinical trial of lacosamide in ALS; 2020. &lt;https://clinicaltrials.gov/ct2/show/NCT03186040#wrapper&gt;.</Citation></Reference><Reference><Citation>Kuzma-Kozakiewicz M., Marchel A., Kaminska A., Gawel M., Sznajder J., Figiel-Dabrowska A., et al. Intraspinal transplantation of the adipose tissue-derived regenerative cells in amyotrophic lateral sclerosis in accordance with the current experts' recommendations: choosing optimal monitoring tools. Stem Cells Int. 2018;2018:4392017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6109475</ArticleId><ArticleId IdType="pubmed">30158984</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X.Y., Liang Z.H., Han C., Wei W.J., Song C.L., Zhou L.N., et al. Transplantation of autologous peripheral blood mononuclear cells in the subarachnoid space for amyotrophic lateral sclerosis: a safety analysis of 14 patients. Neural Regen Res. 2017;12(3):493&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5399730</ArticleId><ArticleId IdType="pubmed">28469667</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingor P., Weber M., Camu W., Friede T., Hilgers R., Leha A., et al. ROCK-ALS: protocol for a randomized, placebo-controlled, double-blind phase IIa trial of safety, tolerability and efficacy of the Rho Kinase (ROCK) inhibitor fasudil in amyotrophic lateral sclerosis. Front Neurol. 2019;10:293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6446974</ArticleId><ArticleId IdType="pubmed">30972018</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L., Ferrero I., Luparello V., Rustichelli D., Gunetti M., Mareschi K., et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a Phase I clinical trial. Exp Neurol. 2010;223(1):229&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">19682989</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H., Salgado E.D., Negroski D., Hanson M.R., Salanga V.D., Wilber J.F., et al. Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials. Neurol. 1986;36(2):152&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">3080695</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D., Liberati A., Tetzlaff J., Altman D.G., Prisma G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabavi S.M., Arab L., Jarooghi N., Bolurieh T., Abbasi F., Mardpour S., et al. Safety, feasibility of intravenous and intrathecal injection of autologous bone marrow derived mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: an open label phase I clinical trial. Cell J. 2019;20(4):592&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6099146</ArticleId><ArticleId IdType="pubmed">30124008</ArticleId></ArticleIdList></Reference><Reference><Citation>Nandedkar S.D., Barkhaus P.E., Stalberg E.V. Motor unit number index (MUNIX): principle, method, and findings in healthy subjects and in patients with motor neuron disease. Muscle Nerve. 2010;42(5):798&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pubmed">20976783</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanaswami P., Spieker A.J., Mongiovi P., Keel J.C., Muzin S.C., Rutkove S.B. Utilizing a handheld electrode array for localized muscle impedance measurements. Muscle Nerve. 2012;46(2):257&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3400114</ArticleId><ArticleId IdType="pubmed">22806375</ArticleId></ArticleIdList></Reference><Reference><Citation>Nefussy B., Artamonov I., Deutsch V., Naparstek E., Nagler A., Drory V.E. Recombinant human granulocyte-colony stimulating factor administration for treating amyotrophic lateral sclerosis: a pilot study. Amyotroph Lateral Scler. 2010;11(1&#x2013;2):187&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">19449238</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuwirth C., Barkhaus P.E., Burkhardt C., Castro J., Czell D., de Carvalho M., et al. Tracking motor neuron loss in a set of six muscles in amyotrophic lateral sclerosis using the Motor Unit Number Index (MUNIX): a 15-month longitudinal multicentre trial. J Neurol Neurosurg Psychiatry. 2015;86(11):1172&#x2013;1179.</Citation><ArticleIdList><ArticleId IdType="pubmed">25935892</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuwirth C., Barkhaus P.E., Burkhardt C., Castro J., Czell D., de Carvalho M., et al. Motor Unit Number Index (MUNIX) detects motor neuron loss in pre-symptomatic muscles in Amyotrophic Lateral Sclerosis. Clin Neurophysiol. 2017;128(3):495&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">28043769</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuwirth C., Braun N., Claeys K.G., Bucelli R., Fournier C., Bromberg M., et al. Implementing Motor Unit Number Index (MUNIX) in a large clinical trial: real world experience from 27 centres. Clin Neurophysiol. 2018;129:1756&#x2013;1762.</Citation><ArticleIdList><ArticleId IdType="pubmed">29803404</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuwirth C., Burkhardt C., Alix J., Castro J., de Carvalho M., Gawel M., et al. Quality control of motor unit number index (MUNIX) measurements in 6 muscles in a single-subject &#x201c;Round-Robin&#x201d; setup. PLoS One. 2016;11(5):e0153948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4852906</ArticleId><ArticleId IdType="pubmed">27135747</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S.B., Vucic S., Cheah B.C., Lin C.S.Y., Kirby A., Mann K.P., et al. Flecainide in amyotrophic lateral sclerosis as a neuroprotective strategy (FANS): a randomized placebo-controlled trial. EBioMedicine. 2015;2(12):1916&#x2013;1922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4703720</ArticleId><ArticleId IdType="pubmed">26844270</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrou P., Gothelf Y., Argov Z., Gotkine M., Levy Y.S., Kassis I., et al. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials. JAMA Neurol. 2016;73(3):337&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">26751635</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugdahl K., Fuglsang-Frederiksen A., Johnsen B., Tankisi H., de Carvalho M., Fawcett P.R., et al. Variation in the neurophysiological examination of amyotrophic lateral sclerosis in Europe. Amyotroph Lateral Scler. 2010;11(5):443&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pubmed">20698806</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney J., Burke T., Vajda A., Heverin M., Hardiman O. What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2017;88(5):381.</Citation><ArticleIdList><ArticleId IdType="pubmed">27888187</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkove S.B., Narayanaswami P., Berisha V., Liss J., Hahn S., Shelton K., et al. Improved ALS clinical trials through frequent at-home self-assessment: a proof of concept study. Ann Clin Transl Neurol. 2020;7(7):1148&#x2013;1157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7359124</ArticleId><ArticleId IdType="pubmed">32515889</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengar N., Dutta M.K., Travieso C.M. IEEE Uttar Pradesh Section International Conference on Electrical, Computer and Electronics (UPCON) 2017. Identification of amyotrophic lateral sclerosis using EMG signals; pp. 468&#x2013;471.</Citation></Reference><Reference><Citation>Shefner J.M., Cudkowicz M.E., Schoenfeld D., Conrad T., Taft J., Chilton M., et al. A clinical trial of creatine in ALS. Neurol. 2004;63(9):1656&#x2013;1661.</Citation><ArticleIdList><ArticleId IdType="pubmed">15534251</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J.M., Rutkove S.B., Caress J.B., Benatar M., David W.S., Cartwright M.S., et al. Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography system. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(7&#x2013;8):555&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6438779</ArticleId><ArticleId IdType="pubmed">30265154</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J.M., Watson M.L., Simionescu L., Caress J.B., Burns T.M., Maragakis N.J., et al. Multipoint incremental motor unit number estimation as an outcome measure in ALS. Neurol. 2011;77(3):235&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136054</ArticleId><ArticleId IdType="pubmed">21676915</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleutjes B., Bystrup Jacobsen A., Tankisi H., Gorkem Sirin N., Emre Oge A., Henderson R.D., et al. Advancing disease monitoring of amyotrophic lateral sclerosis with the compound muscle action potential scan. Clin Neurophysiol. 2021;132:3152&#x2013;3159.</Citation><ArticleIdList><ArticleId IdType="pubmed">34749234</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommer M., Tergau F., Wischer S., Reimers C.-D., Beuche W., Paulus W. Riluzole does not have an acute effect on motor thresholds and the intracortical excitability in amyotrophic lateral sclerosis. J Neurol. 1999;246(3) III22-III6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10631657</ArticleId></ArticleIdList></Reference><Reference><Citation>Statland, J. Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis; 2019. &lt;https://clinicaltrials.gov/ct2/show/NCT03472950#wrapper&gt;.</Citation></Reference><Reference><Citation>van den Berg L.H., Sorenson E., Gronseth G., Macklin E.A., Andrews J., Baloh R.H., et al. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurol. 2019;92(14):e1610&#x2013;e1623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448453</ArticleId><ArticleId IdType="pubmed">30850440</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S., Cheah B.C., Yiannikas C., Kiernan M.C. Cortical excitability distinguishes ALS from mimic disorders. Clin Neurophysiol. 2011;122(9):1860&#x2013;1866.</Citation><ArticleIdList><ArticleId IdType="pubmed">21382747</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S., Henderson R.D., Mathers S., Needham M., Schultz D., Kiernan M.C., et al. Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study. Ann Clin Transl Neurol. 2021;8(10):1991&#x2013;1999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8528453</ArticleId><ArticleId IdType="pubmed">34477330</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S., Kiernan M.C. Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2007;78(8):849&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117729</ArticleId><ArticleId IdType="pubmed">17210625</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S., Kiernan M.C., Menon P., Huynh W., Rynders A., Ho K.S., et al. Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression. BMJ open. 2021;11(1):e041479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7802642</ArticleId><ArticleId IdType="pubmed">33431491</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S., Nicholson G.A., Kiernan M.C. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain. 2008;131:1540&#x2013;1550.</Citation><ArticleIdList><ArticleId IdType="pubmed">18469020</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S., Rutkove S.B. Neurophysiological biomarkers in amyotrophic lateral sclerosis. Curr Opin Neurol. 2018;31(5):640&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pubmed">30080715</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S., Ryder J., Mekhael L., Rd H., Mathers S., Needham M., et al. Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study): Study protocol clinical trial (SPIRIT Compliant) Medicine (Baltimore) 2020;99(6):e18904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7015658</ArticleId><ArticleId IdType="pubmed">32028398</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S., Ziemann U., Eisen A., Hallett M., Kiernan M.C. Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. J Neurol Neurosurg Psychiatry. 2013;84(10):1161&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786661</ArticleId><ArticleId IdType="pubmed">23264687</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger B.J., Macklin E.A., Vucic S., McIlduff C.E., Paganoni S., Maragakis N.J., et al. Effect of ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol. 2021;78(2):186&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7684515</ArticleId><ArticleId IdType="pubmed">33226425</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss M.D., Macklin E.A., McIlduff C.E., Vucic S., Wainger B.J., Kiernan M.C., et al. Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: preliminary findings from a small phase II randomized controlled trial. Muscle Nerve. 2021;63(3):371&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8513796</ArticleId><ArticleId IdType="pubmed">33340120</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells GA, Shea B, O&#x2019;Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses; 2000. &lt;http://www3.med.unipmn.it/dispense_ebm/2009-2010/Corso%20Perfezionamento%20EBM_Faggiano/NOS_oxford.pdf&gt;.</Citation></Reference><Reference><Citation>Wijesekera L.C., Leigh P.N. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009;4(1):3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656493</ArticleId><ArticleId IdType="pubmed">19192301</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu ZY. Explore neuroprotective effect of lipoic acid in amyotrophic lateral sclerosis; 2020. &lt;https://clinicaltrials.gov/ct2/show/NCT04518540#moreinfo&gt;.</Citation></Reference><Reference><Citation>Zanette G., Tamburin S., Manganotti P., Refatti N., Forgione A., Rizzuto N. Different mechanisms contribute to motor cortex hyperexcitability in amyotrophic lateral sclerosis. Clin Neurophysiol. 2002;113(11):1688&#x2013;1697.</Citation><ArticleIdList><ArticleId IdType="pubmed">12417221</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x17b;mijewska N, &#x15a;wi&#x105;tkowska-Flis B. The Evaluation of the Effect of Mesenchymal Stem Cells on the Immune System of Patients With ALS (ALSTEM); 2020. &lt;https://clinicaltrials.gov/ct2/show/NCT04651855&gt;.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>